• Clinical Insights: January 22, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval BalcoltraTM (levonorgestrel and ethinyl estradiol and ferrous bisglycinate) – January 19, 2018 – Avion Pharmaceuticals, LLC, received approval of its new drug application (NDA) for the oral contraceptive… Read more »

  • Clinical Insights: January 15, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval No new updates.   New Formulation Approval No new updates.   New Indication Approval Lynparza® (olaparib) – January 12, 2018 – The Food and Drug Administration… Read more »

  • Join Us at the 340B Coalition Winter Conference!

    Join the RxStrategies team at the 340B Coalition Winter Conference in San Diego, California February 21-23. Here, your team can stay up to date on the latest news, trends and regulations in the 340B program to best maintain compliance. We look forward to connecting with industry leaders while gaining insight on 340B happenings and issues… Read more »

  • Maintain 340B Program Compliance in 2018

    RxStrategies works with Covered Entities to provide an integrated approach to streamline the delivery of quality care, while maximizing savings and meeting the regulatory challenges associated with 340B program management. RxStrategies’ 340B solutions are key to a comprehensive and compliant 340B program.  RxStrategies’ CompliancePlus Audit Solution (Self-Audit Portal) Implement internal processes, controls and protocols that… Read more »

  • Clinical Insights: January 2, 2018

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lumify™ (brimonidine tartrate) – New OTC Drug Approval – December 22, 2017 – Bausch + Lomb, a leading global eye health company and wholly owned subsidiary… Read more »

  • Maintain a Compliant 340B Program in Your Hospital

    Through RxStrategies’ hospital-focused services, hospitals can manage and track grant funded subsidies, manage 340B product purchases and inventory, participate in P&T committees, manage pharmacies, receive consulting services to improve financial, operational and strategic management and more. The comprehensive solutions that allow hospitals to maintain a compliant 340B program include: Split Billing – Addresses the complexity… Read more »

  • December 2017 – 340B Insider

      Welcome to the December edition of RxStrategies’ 340B Insider, a concise communication to provide a quick highlight of updates from RxStrategies’ view. 340B HEALTH URGES ACTION: Stop 340B Hospital Cuts The time is now to contact your Senators and Representatives regarding H.R. 4392 to stop the $1.6 billion in cuts effective Jan. 1, 2018. RxStrategies… Read more »

  • Clinical Insights: December 12, 2017

    Welcome to the weekly edition of RxStrategies Clinical Insights, designed to help pharmacy professionals stay up to date on the ever-changing pharmaceutical and pharmacy market place.   New Drug Approval Lonhala™ Magnair™ (glycopyrrolate) – December 5, 2017 – Sunovion Pharmaceuticals Inc. (Sunovion) announced that the U.S. Food and Drug Administration (FDA) approved the New Drug Application… Read more »

  • Ensure and Maximize 340B Program Compliance

    We assist retail and specialty pharmacies in ensuring 340B program security, efficiency and safety. With this solution, you will be able to maximize compliance, visibility, capture rate, inventory reconciliation and more.   Key Elements of Our Enterprise Backbone for Retail and Specialty Pharmacies • Serves as data clearinghouse for all your contracted TPAs (Third Party… Read more »